Related references
Note: Only part of the references are listed.Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study
A. Rogiers et al.
SUPPORTIVE CARE IN CANCER (2020)
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
Caroline Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
Y. J. L. Jansen et al.
ANNALS OF ONCOLOGY (2019)
Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).
Hussein Abdul-Hassan Tawbi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics
Romain-David Seban et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
Teofila Seremet et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy
Amadeus Schraag et al.
EUROPEAN JOURNAL OF RADIOLOGY (2019)
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Richard W. Joseph et al.
CLINICAL CANCER RESEARCH (2018)
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
Scott J. Rodig et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma
A. C. Tan et al.
ANNALS OF ONCOLOGY (2018)
4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
21PBaseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumab
G Awada et al.
ANNALS OF ONCOLOGY (2018)
Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function
Young-hee Lee et al.
CELL RESEARCH (2017)
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
J. H. Lee et al.
ANNALS OF ONCOLOGY (2017)
Correlation between baseline characteristics and clinical outcome of patients with advanced melanoma treated with pembrolizumab (PEMBRO)
Y. Jansen et al.
ANNALS OF ONCOLOGY (2016)
Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma
S. Diem et al.
BRITISH JOURNAL OF CANCER (2016)
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Benjamin Weide et al.
CLINICAL CANCER RESEARCH (2016)
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil I. Daud et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2016)
The cancer immunogram
Christian U. Blank et al.
SCIENCE (2016)
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
Santiago Zelenay et al.
CELL (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Share Paper
